-
公开(公告)号：EP4393720A1
公开(公告)日：2024-07-03
申请号：EP22307068.1
申请日：2022-12-30
申请人： ARKEMA FRANCE
发明人： JEPSON, David , SQUIRES, Kelly , SEHNAL, Petr , PLENDERLEITH, Richard , LIU, Sen , QUEK, Sophie , REN, Kangtai , MACNEILL, Christopher , CALDERLEY, Nicholas
IPC分类号： B41M7/00 , C08F2/00 , C08K5/00 , C09D11/38 , G03F7/00 , C07F9/53 , C07F9/6509 , C07F9/6533
CPC分类号： C07F9/650952 , C07F9/6533 , C09D11/38 , C08K5/00 , G03F7/00 , C07F9/5337 , C09D11/101 , C08F2/50
摘要： The present invention relates to a phosphine oxide-based photoinitiator, to a process for preparing said photoinitiator and to a precursor that may be used to prepare said photoinitiator. The present invention further relates to a photoinitiator composition, to a curable composition, to a process for the preparation of a cured product, to a process of inkjet printing, to a process of 3D printing and to a process for coating a nail. The invention also relates to precursors of the photoinitiator or the photoinitiator composition. The invention also relates to the use of the photoinitiator or the photoinitiator composition.
-
公开(公告)号：EP2721019A1
公开(公告)日：2014-04-23
申请号：EP12800001.5
申请日：2012-06-18
发明人： CAO, Sheldon , POPOVICI-MULLER, Janeta , SALITURO, Francesco G. , SAUNDERS, Jeffrey, O. , TRAVINS, Jeremy , TAN, Xuefei , YAN, Shunqi , YE, Zhixiong
IPC分类号： C07D401/04 , C07D401/02 , C07D401/14 , C07D405/00 , A61K31/44 , A61K31/4427 , A61P35/00
CPC分类号： C07F9/650952 , A61K31/496 , A61K31/498 , A61K31/4985 , A61K31/501 , A61K31/502 , A61K31/506 , A61K31/517 , A61K31/5377 , A61K31/675 , C07D213/85 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D498/04 , C07F9/65583
摘要： Provided are compounds with the following structure, formula (I) pharmaceutically acceptable salts thereof, use of those compounds for treating cancer and pharmaceutical compositions comprising those compounds.
-
3.发明公开
公开(公告)号：EP4368626A1
公开(公告)日：2024-05-15
申请号：EP23209387.2
申请日：2023-11-13
发明人： CHENG, Felice , CHENG, Ping-Fu , HWANG, Jenn-Tsang , FU, Chih-Wei , LIN, Ku-Feng , CHIU, Ya-Ling , LI, Jheng-Sian , WANG, Kang-Li , CHANG, Siou-Han , FAN, Chia-Yu
IPC分类号： C07F9/09 , C07F9/12 , C07F9/53 , C07F9/6509 , C07F9/6512
CPC分类号： C07F9/6512 , C07F9/5304 , C07F9/091 , C07F9/532 , C07F9/650952 , C07F9/12 , A61K9/127
摘要： A lipid compound or a derivative thereof and a pharmaceutical composition employing the same are provided. The lipid compound has a structure represented by Formula (I):
wherein Z1, Z2, Z3 and Z4 are as disclosed in the specification.-
公开(公告)号：EP3183242A1
公开(公告)日：2017-06-28
申请号：EP15756772.8
申请日：2015-08-20
发明人： XIAO, Hai-Yun , DYCKMAN, Alaric J. , XIAO, Zili , YANG, Michael G. , DHAR, T.G. Murali , GILMORE, John L. , MARCOUX, David
IPC分类号： C07D309/06 , A61K31/133 , A61K31/135 , A61K31/353 , A61K31/36 , A61K31/47
CPC分类号： A61K31/695 , A61K31/135 , A61K31/137 , A61K31/15 , A61K31/165 , A61K31/166 , A61K31/17 , A61K31/222 , A61K31/24 , A61K31/27 , A61K31/337 , A61K31/351 , A61K31/352 , A61K31/381 , A61K31/415 , A61K31/4174 , A61K31/426 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/47 , A61K31/4965 , A61K31/505 , A61K31/661 , C07B2200/05 , C07C215/42 , C07C217/52 , C07C217/58 , C07C217/74 , C07C219/24 , C07C233/41 , C07C233/65 , C07C235/46 , C07C251/38 , C07C251/42 , C07C251/44 , C07C251/50 , C07C251/52 , C07C251/54 , C07C271/34 , C07C275/26 , C07C317/28 , C07C317/32 , C07C321/16 , C07C321/22 , C07C321/28 , C07C323/25 , C07C323/29 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2602/10 , C07C2603/74 , C07D209/46 , C07D213/32 , C07D213/38 , C07D213/69 , C07D213/70 , C07D215/12 , C07D215/14 , C07D217/24 , C07D231/12 , C07D231/20 , C07D239/26 , C07D241/04 , C07D241/12 , C07D277/24 , C07D305/08 , C07D309/06 , C07D309/12 , C07D311/58 , C07D311/76 , C07D319/20 , C07D333/16 , C07F7/0818 , C07F9/091 , C07F9/117 , C07F9/5442 , C07F9/5728 , C07F9/62 , C07F9/65031 , C07F9/650952 , C07F9/65522 , C07F9/655345
摘要： and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
摘要翻译： 和/或其盐，其中R1是-OH或-OP（O）（OH）2，并且X1，X2，X3，R2，R2a，Ra，Rb和Rc如本文所定义。 还公开了使用这种化合物作为G蛋白偶联受体S1P1的选择性激动剂的方法，以及包含这些化合物的药物组合物。 这些化合物可用于治疗，预防或减缓各种治疗领域中的疾病或病症如自身免疫疾病和血管疾病的进展。
-
公开(公告)号：EP2721019A4
公开(公告)日：2014-11-19
申请号：EP12800001
申请日：2012-06-18
发明人： CAO SHELDON , POPOVICI-MULLER JANETA , SALITURO FRANCESCO G , SAUNDERS JEFFREY O , TRAVINS JEREMY , TAN XUEFEI , YAN SHUNQI , YE ZHIXIONG
IPC分类号： C07D213/85 , A61K31/44 , A61K31/496 , A61P35/00 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D498/04
CPC分类号： C07F9/650952 , A61K31/496 , A61K31/498 , A61K31/4985 , A61K31/501 , A61K31/502 , A61K31/506 , A61K31/517 , A61K31/5377 , A61K31/675 , C07D213/85 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D498/04 , C07F9/65583
摘要： Provided are compounds with the following structure, formula (I) pharmaceutically acceptable salts thereof, use of those compounds for treating cancer and pharmaceutical compositions comprising those compounds.
-
公开(公告)号：EP2185570A4
公开(公告)日：2011-02-09
申请号：EP08827446
申请日：2008-08-13
发明人： TIAN FENG , DANG QUN , PRASAD G SRIDHAR , LI WENYU , BOOKSER BRETT C , RAFFAELE NICHOLAS BRIAN , ERION MARK D
IPC分类号： C07F9/02 , A61K31/675 , A61P3/00 , C07C233/11
CPC分类号： C07F9/65586 , C07C233/11 , C07F9/3834 , C07F9/4021 , C07F9/582 , C07F9/587 , C07F9/65033 , C07F9/650952 , C07F9/650964 , C07F9/65122 , C07F9/653 , C07F9/6539 , C07F9/65392 , C07F9/65395 , C07F9/65397 , C07F9/6541 , C07F9/655345 , C07F9/65583 , C07F9/6561 , C07F9/65616 , C07F9/657181
摘要： The present invention provides for novel compounds of Formulas I and II and pharmaceutically acceptable salts and co-crystals thereof which have glucokinase activator activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucokinase activator is indicated, including Type 1 and 2 diabetes, impaired glucose tolerance, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formulas I and II, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.
-
公开(公告)号：EP4355753A1
公开(公告)日：2024-04-24
申请号：EP22735831.4
申请日：2022-06-15
IPC分类号： C07F9/50 , A61P35/00 , C07F9/6544 , C07F9/6536 , C07F9/6509
CPC分类号： C07F9/6536 , C07F9/6544 , C07F9/650952 , C07F9/5045 , A61P35/00
-
公开(公告)号：EP3045463B1
公开(公告)日：2018-10-03
申请号：EP14862404.2
申请日：2014-11-17
申请人： LG Chem, Ltd.
发明人： SA, Seok Pil , LEE, Yong Ho , LEE, Ki Soo , SHIN, Eun Ji
CPC分类号： B01J31/2409 , B01J31/143 , B01J2231/20 , B01J2531/002 , B01J2531/62 , C07C2/32 , C07C2531/12 , C07C2531/14 , C07C2531/22 , C07C2531/24 , C07F9/28 , C07F9/46 , C07F9/572 , C07F9/58 , C07F9/6506 , C07F9/650952 , C07F9/65515 , C07F9/655345 , C08F4/42 , C08F110/02 , C07C11/107 , C07C11/02
摘要： The present invention relates to a ligand compound, a catalyst system for olefin oligomerization, and a method for olefin oligomerization using the same. The present ligand compound is a compound having a certain new structure and enables provision of a catalyst system for olefin oligomerization that can oligomerize ethylene with higher catalytic activity.
-
9.发明公开LIGAND COMPOUND, CATALYST SYSTEM FOR OLEFIN OLIGOMERIZATION, AND OLEFIN OLIGOMERIZATION METHOD USING THE SAME 审中-公开LIGANDVERBINDUNG，KATALYSATYSYSTEM ZUR OLEFINOLIGOMERISIERUNG UND OLEFINOLIGOMERISIERUNGSVERFAHREN DAMIT
公开(公告)号：EP3045463A1
公开(公告)日：2016-07-20
申请号：EP14862404.2
申请日：2014-11-17
申请人： LG Chem, Ltd.
发明人： SA, Seok Pil , LEE, Yong Ho , LEE, Ki Soo , SHIN, Eun Ji
CPC分类号： B01J31/2409 , B01J31/143 , B01J2231/20 , B01J2531/002 , B01J2531/62 , C07C2/32 , C07C2531/12 , C07C2531/14 , C07C2531/22 , C07C2531/24 , C07F9/28 , C07F9/46 , C07F9/572 , C07F9/58 , C07F9/6506 , C07F9/650952 , C07F9/65515 , C07F9/655345 , C08F4/42 , C08F110/02 , C07C11/107 , C07C11/02
摘要： The present invention relates to a ligand compound, a catalyst system for olefin oligomerization, and a method for olefin oligomerization using the same. The present ligand compound is a compound having a certain new structure and enables provision of a catalyst system for olefin oligomerization that can oligomerize ethylene with higher catalytic activity.
摘要翻译： 本发明涉及配体化合物，烯烃低聚的催化剂体系，以及使用该化合物的烯烃低聚方法。 本发明的配体化合物是具有一定新结构的化合物，能够提供可以以更高的催化活性使乙烯低聚的烯烃低聚催化剂体系。
-
10.发明公开SUBSTITUTED 4 - PHENYL - PYRIDINES FOR THE TREATMENT OF NK-1 RECEPTOR RELATED DISEASES 有权取代的4-苯基吡啶，NK-1受体介导的疾病治疗
公开(公告)号：EP2785706A1
公开(公告)日：2014-10-08
申请号：EP12798549.7
申请日：2012-11-28
发明人： FADINI, Luca , MANINI, Peter , PIETRA, Claudio , GIULIANO, Claudio , LOVATI, Emanuela , CANNELLA, Roberta , VENTURINI, Alessio , STELLA, Valentino, J.
IPC分类号： C07D401/04 , A61K31/44 , A61P25/00
CPC分类号： C07F9/650952 , A61K31/44 , A61K31/473 , A61K31/496 , A61K31/56 , A61K31/675 , A61K45/06 , C07D213/74 , C07D213/89 , C07D401/04
摘要： Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor. The compounds have the general formula (I):
-
-
-
-
-
-
-
-
-
搜索结果
20 条记录 (耗时 0.019 秒)
